Year :

The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy

First investigational product being recommended for Breakthrough Therapy Designation in China SOMERSET, NJ, August 5, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) announcedtoday that the China Center for Drug Evaluation, National Medical Products Administration(CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for ciltacabtageneautoleucel (cilta-cel; LCAR-B38M CAR-T cells), an investigational B-cell maturation antigen(BCMA) targeted chimeric antigen […]

Aug 05, 2020

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications


You are about to leave

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.